Skip to main content
Evidence Snapshot

Sigma 2 receptor

CHEMBL613288 UNKNOWN
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:14Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613288
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Sigma 2 receptor as ChEMBL target CHEMBL613288. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Sigma 2 receptor
UNKNOWN
As of 2026-09-14
ChEMBL target ID
CHEMBL613288
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Sigma 2 receptor matters

As of 2026-09-14

Sigma 2 receptor is reviewed as Sigma 2 receptor; the current evidence base includes 3 approved drugs, 587 compounds, and 65 assays, with lead potency reaching pChEMBL 10.8.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 3 approved drugs, 587 compounds, and 65 assays for this target. The dominant activity type is KI. CHEMBL129145 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL129145 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine
3 approved pChEMBL 10.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Sigma 2 receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

587
Total Compounds
65
Total Assays
3
Approved Drugs
IC50: 88.0, KI: 550.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL129145
 10.8 IC50 —
No preferred name
CHEMBL337974
 10.5 IC50 —
No preferred name
CHEMBL64683
 10.3 IC50 —
No preferred name
CHEMBL61479
 9.9 IC50 Clinical
No preferred name
CHEMBL59273
 9.8 IC50 —

Approved Drugs

Structure Compound First Approval
HALOPERIDOL
CHEMBL54
 1967
CARBETAPENTANE
CHEMBL73234
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:14Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613288